Identifai Genetics Limited commenced trading on the Australian Securities Exchange under the ticker code ID1 on October 13, 2026, following an initial public offering that raised A$10 million at A$0.20 per share. The company is developing Windrose, a non-invasive prenatal screening platform intended to assess selected inherited conditions from a single maternal blood sample. The new capital will support clinical validation, US laboratory readiness, and further product development ahead of a planned market entry.
Windrose Platform and Clinical Purpose
Windrose combines genomic sequencing with proprietary computational analysis, including artificial intelligence and machine learning, to predict fetal genetic variants within maternal blood. The workflow relies on a single maternal blood sample and does not require a paternal sample. Sample collection is designed to begin at approximately nine weeks of pregnancy, with the goal of giving clinicians and families earlier information for further investigation and care planning.
The technology originated from research by Professor Noam Shomron and Dr Tom Rabinowitz at Tel Aviv University and was established in 2021 by ShizimVS Innovation Center. Identifai's intellectual property portfolio comprises 11 patent families supported by more than a decade of accumulated research. The company is focused on selected inherited conditions where earlier findings may support specialist referral, delivery planning, or preparation for neonatal care.
US Commercialization Strategy and Study Plans
The United States is the first target commercial market for Identifai, and Aesir Corporate acted as lead manager for the IPO. The company will prioritize US laboratory readiness and assay validation, including applicable Clinical Laboratory Improvement Amendments certification requirements. It also plans a multicenter clinical validation study in the US targeting approximately 600 participants to evaluate Windrose in an intended clinical setting.
CEO Eyal Miller said the ASX listing is an important step in translating Identifai's research into a product for prenatal care. He added that immediate priorities include laboratory readiness, the planned clinical validation program, and staged product releases while the company pursues commercial partnerships. The company also intends to continue development of its next-generation Windrose+ program.
Leadership and Scientific Foundation
Co-founder and Chief Scientific Officer Professor Noam Shomron leads the scientific program alongside CEO Eyal Miller and the research and operations team. Co-founder Yossi Bornstein serves as Chairman of the Board. Professor Shomron said the research began with a clear objective to obtain meaningful fetal genetic information from a maternal blood sample early enough to guide clinical care.
Next Steps and Market Outlook
Following the listing, Identifai will focus on generating clinical evidence and establishing the laboratory capabilities required for the US market. The company stated that screening findings may require confirmatory diagnostic testing and that future updates will cover material development, clinical validation, and commercial milestones. Its broader ambition is to make earlier, clinically relevant genetic information more accessible through a single maternal blood sample.
Identifai Genetics enters the public market with a defined US-first strategy and a technology platform supported by more than a decade of research. The A$10 million IPO provides near-term funding for validation, laboratory preparation, and clinical study activity, positioning the company to advance Windrose toward staged product releases. Investors and prenatal care stakeholders will be watching for progress on laboratory certification, trial enrollment, and commercial partnerships over the coming months.